"Lipopeptides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds consisting of a short peptide chain conjugated with an acyl chain.
| Descriptor ID |
D055666
|
| MeSH Number(s) |
D10.477 D12.644.365
|
| Concept/Terms |
Anionic Lipopeptides- Anionic Lipopeptides
- Lipopeptides, Anionic
- Anionic Lipopeptide
- Lipopeptide, Anionic
Cationic Lipopeptides- Cationic Lipopeptides
- Lipopeptides, Cationic
- Cationic Lipopeptide
- Lipopeptide, Cationic
|
Below are MeSH descriptors whose meaning is more general than "Lipopeptides".
Below are MeSH descriptors whose meaning is more specific than "Lipopeptides".
This graph shows the total number of publications written about "Lipopeptides" by people in this website by year, and whether "Lipopeptides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 12 | 9 | 21 |
| 2018 | 6 | 6 | 12 |
| 2019 | 3 | 1 | 4 |
| 2020 | 5 | 1 | 6 |
| 2021 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Lipopeptides" by people in Profiles.
-
Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus. Emerg Microbes Infect. 2021 Dec; 10(1):810-821.
-
Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. Emerg Microbes Infect. 2021 Dec; 10(1):1227-1240.
-
SARS-CoV-2-derived fusion inhibitor lipopeptides exhibit highly potent and broad-spectrum activity against divergent human coronaviruses. Signal Transduct Target Ther. 2021 08 03; 6(1):294.
-
Lipopeptides for Vaccine Development. Bioconjug Chem. 2021 08 18; 32(8):1472-1490.
-
Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection. Microbes Infect. 2021 Sep-Oct; 23(8):104840.
-
Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science. 2021 03 26; 371(6536):1379-1382.
-
Translation of Mycobacterium Survival Strategy to Develop a Lipo-peptide based Fusion Inhibitor*. Angew Chem Int Ed Engl. 2021 03 08; 60(11):6101-6106.
-
Reducing transmission of SARS-CoV-2 with intranasal prophylaxis. EBioMedicine. 2021 Jan; 63:103170.
-
Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. EBioMedicine. 2021 Jan; 63:103153.
-
Immune Modulation to Improve Survival of Viral Pneumonia in Mice. Am J Respir Cell Mol Biol. 2020 12; 63(6):758-766.